Cognoa Research

Die Cognoa ASD Dx Research-App steht nur Studienteilnehmern zur Verfügung.

The American Academy of Pediatrics believes that early intervention is critical for children with developmental delays. However, most children in the U.S. are diagnosed with delays such as autism after the age when treatments have the greatest opportunity for lifelong impact. Cognoa Inc. has developed diagnostic software based on machine learning technology to help healthcare providers identify children with autism as early as possible in the primary care setting.

The purpose of the Cognoa ASD Diagnosis Aid Validation Study is to assess the ability of the device to aid in the diagnosis of ASD. The device is intended for investigational use only. The performance characteristics of this product have not been established.

NOTE:

To access the Cognoa ASD Research app, you must be enrolled in a study. If you are interested in participating you may contact [email protected] for more information.

ABOUT COGNOA:

Cognoa, Inc. is developing AI-based digital diagnostics and personalized therapies to make earlier diagnoses and effective treatments available to more children to improve outcomes and lower behavioral healthcare costs. When more physicians are empowered to identify and begin treating behavioral conditions and developmental delays earlier, more children have the opportunity to benefit from treatments at a younger age when there is the greatest potential for improved lifelong outcomes.